Evidence-based medicine and medicine-based evidence

Neurological Sciences

Volumn 26, Issue 3, 2005, Pages 145-146

  Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CHARLES BONNET SYNDROME; CLINICAL PRACTICE; DELUSION; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INFORMATION RETRIEVAL; INFORMED CONSENT; LOW DRUG DOSE; MEDICAL DECISION MAKING; METABOLIC SYNDROME X; NOTE; PATHOPHYSIOLOGY; PATIENT CARE; PRESCRIPTION; REIMBURSEMENT; RISK FACTOR; SCHIZOPHRENIA; TREATMENT INDICATION; VISUAL HALLUCINATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EVIDENCE-BASED MEDICINE; HALLUCINATIONS; HUMANS;

EID: 23944443532     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0451-4     Document Type: Note

References (6)

1. Haynes B, Haines A (1998) Barriers and bridges to evidence based clinical practice. BMJ 317:273-276
2. Coletti Moja M, Milano E, Gasverde S, Gianelli M, Giordana MT (2005) Olanzapine therapy in hallucinatory visions related to Bonnet Syndrome. Neurol Sci 26:168-170
3. Eperjesi F, Akbarali N (2004) Rehabilitation in Charles Bonnet syndrome: a review of treatment options. Clin Exp Optom 87:149-152
4. Koponen H, Saari K, Savolainen M, Isohanni M (2002) Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: A review. Eur Arch Psychiatry Clin Neurosci 252:294-298
5. Newcomer JW (2004) Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65[Suppl 18]:36-46
6. Knottnerus JA, Dinant GJ (1997) Medicine based evidence, a prerequisite for evidence based medicine. BMJ 315:1109-1110